Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA to assess whether claims such as '#1 prescribed' affect consumer views of drug product; project to cost $529,742. Chart notes price tag for 18 other DTC studies.

Advertisement

Related Content

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
DTC Animation Study Moving Forward After FDA Rejects Merck Critique
DTC Safety Messages Could Vary By Platform As FDA Considers Screen Size
FDA's Rx Promotion Citation Drought Continued In 2015
DTC Advertising For ADHD, Acne, Antidepressant Meds Could Shift After FDA Study
FDA’s Biggest DTC Advertising Study Eyes Online Promotion
FDA Revises Prescriber DTC Survey To Focus On Patient Interactions
The Drug Olympics: FDA To Test Consumer Comprehension Of Composite Endpoints
FDA To Study Impact Of Rx Drug Ads That Provide Disease Information
FDA’s DTC Coupon Study Triggers First Amendment Objections From PhRMA

Topics

Advertisement
UsernamePublicRestriction

Register

PS078752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel